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Background: Spirometry is used to diagnose chronic obstructive pulmonary disease (COPD). The
Impulse oscillometry system (IOS) allows determination of respiratory impedance indices, which
might be of potential value in early COPD, although previous experience is limited. We examined
pulmonary resistance and reactance measured by IOS in subjects with or without self-reported
chronic bronchitis or emphysema or COPD (Qþ or Q) and subjects with or without COPD diagnosed
according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria (Gþ or G).
Methods: From a previous population-based study 450 subjects were examinedwith spirometry and
IOS and answered a questionnaire on respiratory symptoms and diseases.
Results: Seventy-seven subjects were Qþ, of whom 34 also were Gþ. Qþ/G subjects (nZ 43) re-
ported respiratory symptomsmore frequently (35e40% vs 8e14%) but had higher FEV1 (100% vs 87%)
than Q/Gþ subjects (nZ 90), p< 0.05 for both comparisons. Qþ subjects had higher pulmonary
resistanceand lowerpulmonary reactance thanQ subjects (p< 0.01 forall comparisons).The same
pattern was seen both in Gþ subjects ((Qþ/Q) R5 0.39/0.32, R5eR20 0.10/0.07, X5 0.13/0.09, AX
0.55/0.27, p < 0.05 for all) and G subjects ((Qþ/Q) R5 0.35/0.29, R5eR20 0.08/0.06, X5 0.10/
0.08, AX 0.31/0.19 p< 0.05 for all) except for R20 (adjusted for gender and age).
Conclusions: Self-reported chronic bronchitis or emphysema or COPD was associated with higher
pulmonary resistance and lower pulmonary reactance measured by IOS, both among subjects with
and without COPD according to GOLD criteria. IOS may have the potential to detect pathology asso-
ciated with COPD earlier than spirometry.
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Impulse oscillometry in detecting early manifestations of COPD 1117Introduction lungs”) performed in a population-based cohort in 1992 as
18,19Chronic obstructive pulmonary disease (COPD) is characterized
by chronic, progressive airway obstruction and can be diag-
nosed by spirometry.1 Major treatment guidelines, e.g. the
global initiative for obstructive lung disease (GOLD 2010)
recommend that COPD should be identified as early as possible
in order to increase the opportunity to affect disease progres-
sion.1 Most COPD patients experience respiratory symptoms
suchasdyspnoea, coughand sputumproduction,but the roleof
symptoms in early detection of COPD is unclear. Studies by de
Marco et al.2 and Lindberg et al.3 suggest that the presence of
chronic cough/phlegm identifies subjects at risk of COPD
independent of smoking habits. However, longitudinal data
from theCopenhagenHeart Study did not show that productive
cough was a predictor of COPD development.4 Furthermore,
respiratory symptoms may not always be adequately reported
and there is also a poor relationship between respiratory
symptoms and spirometric variables.1,5
Respiratory mechanics can also be measured by forced
oscillation measurements.6e8 A commercially available
method is provided by the Impulse Oscillometry System (IOS)
(MasterScreen IOS, Viasys GmbH, Hoechberg, Germany). IOS
assesses pulmonary resistance (Rrs) and reactance (Xrs),
which are the real and imaginary part of respiratory imped-
ance (Zrs), at various frequencies. Oscillometry has been
proposed to be able to reflect more distal airway function9
compared to spirometry10,11 and distal airways are a major
site for airway obstruction in COPD.12e15 A clinical advantage
of this method is that it is performed during tidal breathing
and requires no forced manoeuvres. The relevance of this
method in COPD is still somewhat unclear, but an association
between reactance and FEV1 in COPD patients has been
shown.16 Another study showed a correlation between IOS
measurements and health status and dyspnoea among COPD
patients.17 These studies did not include control groups, and
it is not clear what information IOS contributes in subjects
with symptoms of COPD but normal spirometry.
The objective of this study was to examine pulmonary
resistance and reactance measured by IOS in subjects with or
without self-reported chronic bronchitis or emphysema or
COPD (according to a questionnaire on respiratory diseases and
symptoms, Qþ/Q) and subjects with or without COPD diag-
nosed according to the GOLD criteria (Gþ/G). Our primary
hypothesis was that pulmonary resistance is higher and reac-
tance lower among subjects reporting respiratory symptoms in
a group of subjects not fulfilling the spirometric criteria for
COPD according to GOLD and that this may indicate early
manifestations of COPD.
Methods
This was a cross sectional study including one clinic visit at
the Department of Clinical Physiology, Malmo¨ University
Hospital (UMAS) in Malmo¨.
Study population
The invited study population consisted of 870 invited
subjects, who comprised a sub-population to a postal
respiratory questionnaire survey (“Questions about thewell as 2000. Three different groups of subjects all
residing in the area of Malmo¨, Southern Sweden were
recruited; (1) Lung healthy never-smokers Z subjects who
did not report any respiratory symptoms and never had
smoked (2) Lung healthy current smokers Z subjects who
did not report any respiratory symptoms and were current
smokers and (3) Subjects with COPD Z subjects who
responded that they had or had had a diagnosis of chronic
bronchitis or emphysema or COPD.
At the study visit, subjects were classified according to
their current smoking habits (current smokers, ex-smokers
and never-smokers), their answers to the repeated ques-
tionnaire and their spirometry results according to the
GOLD 2010 criteria.
Ethic approval
The study was approved by the Ethics Committee of Lund
University and participants signed an informed consent
before any study related procedure.
Questionnaire
Questions about the lungs
This questionnaire was used both for study recruitment
purposes and for classification of several respiratory
symptoms at the study visit. “Questions about the lungs” is
a questionnaire about respiratory diseases and symptoms
that has been used in several previous surveys and is
described elsewhere.18
Self-reported chronic bronchitis or emphysema or COPD
Self-reported chronic bronchitis or emphysema or COPD
(Qþ) was defined as a positive answer to any of the ques-
tions “Do you have or have had chronic bronchitis or
emphysema or chronic obstructive pulmonary disease
(COPD)?” and “Did you get the diagnosis chronic bronchitis
or emphysema or chronic obstructive pulmonary disease
(COPD) by a physician?”
Chronic bronchitis, long-standing cough and use of
pulmonary medication
Symptoms of chronic bronchitis (CB) were defined as
a positive answer to “Have you had periods of 3 months
with cough with phlegm during 2 years in a row during the
last years?”. Long-standing cough was defined as a positive
answer to “Have you had long-standing cough during the
last 12 months?”. Any use of pulmonary medication was
defined as a positive answer to “Do you regularly take or
have taken any pulmonary medication?”.
Smoking habits
Subjects who currently smoked or had stopped smoking
within the last 12 months prior to the study visit were
classified as smokers. Subjects who had stopped smoking
more than 12 months prior to the study visit were classified
as ex-smokers. Subjects who had never been smoking daily
for more than one month were classified as never-smokers.
The total tobacco consumption was calculated in pack-
Figure 1 Flow chart demonstrating the classification of
participants. Among subjects with no self-reported respiratory
disease (n Z 342) 252 subjects did not fulfil the spirometric
criteria for COPD according to GOLD (Q/G) and 90 subjects
did (Q/Gþ). Among subjects with self-reported respiratory
disease (n Z 77) 43 subjects did not fulfil the spirometric
criteria for COPD according to GOLD (Qþ/G) and 34 subjects
did (Qþ/Gþ).
1118 S. Frantz et al.years (one pack year Z 20 cigarettes smoked per day for
one year).
Lung function tests
All lung function measurements were made 15e45 min
after inhalation of 1.0 mg of terbutaline (Bricanyl
Turbuhaler).
Spirometry
Spirometry was performed according to the standards of
the European Respiratory Society (ERS)20 and European
reference values were used.20 A spirometer (Master Screen,
Viasys GmbH e Erich Jaeger, Hoechberg, Germany) was
used to measure forced expiratory volume in one second
(FEV1) and vital capacity (VC).
IOS
The pulmonary resistance and reactance was measured
using IOS (MasterScreen IOS, Viasys GmbH, Hoechberg,
Germany). The device consists of a loudspeaker that
generates pressure oscillations composed of multiple
frequencies, which are superimposed during 30 s of normal
tidal breathing. This allows the assessment of resistance
and reactance at several frequencies simultaneously,
ranging from 5 to 35 Hz. Subjects sat upright, had a nose
clip and firmly supported their cheeks with their hands. A
minimum of three trials were performed. The following
variables were evaluated: I. Respiratory resistance at 5 Hz
(R5), which is assumed to reflect total airways resistance,
II. Respiratory resistance at 20 Hz (R20), which is assumed
to reflect central airways resistance, III. The fall in resis-
tance from R5 to R20 (R5eR20) was used as a surrogate for
the frequency dependence of respiratory resistance, which
increases with increasing inhomogeneity of peripheral
airways,10,11 IV. Distal capacitive reactance at 5 Hz (X5),
which is assumed to reflect peripheral airways function and
V. An area index of low frequent reactance (AX). This
parameter incorporates the area, which ranges from the
negative reactance between 5 Hz and resonant frequency
to the zero line.
Classification and staging of COPD
COPD was diagnosed according to the GOLD (Global initia-
tive for chronic Obstructive Lung Disease) criteria (www.
goldcopd.org, version 2010). Also staging of COPD severity
was performed according to the GOLD criteria with stage I
(mild): FEV1  80% of predicted normal (PN), stage II
(moderate): 50%  FEV1 < 80% PN, stage III (severe):
30%  FEV1 < 50% PN, and stage IV (very severe COPD):
FEV1 < 30% PN.
Statistical analyses
IBM SPSS Statistics 18 (SPSS Inc., Chicago, Illinois 60606) was
used for the statistical analyses. One-way ANOVA was used
for comparisons of continuous variables. Continuous vari-
ables not normally distributed (IOS variables) were log-
transformed before the analyses. The mean values of IOS
variables in the four study groups were adjusted for age andgender and compared in a general linear model. As the IOS
variables had skewed distributions the variables were log-
transformed before the general linear model analysis. Log-
transformed values were back transformed after the
statistical analyses and presented as geometric means.
Categorical variables were compared using Chi-squared
analysis. A p-value of <0.05 was considered statistically
significant.Results
Participation
Of the 870 invited subjects 450 subjects (52%) participated.
The participation rates for lung healthy never-smokers,
lung healthy current smokers and subjects with self-
reported COPD were 50% (n Z 60), 50% (n Z 282) and
57% (n Z 108), respectively.Characteristics of the study population
At the study visit subjects were classified into four different
groups based on spirometry results and current answers to
the questionnaire: Q/G, Q/Gþ, Qþ/G and Qþ/Gþ
(Fig. 1). Thirty-one participants were excluded from the
analyses due to incomplete answers to the questionnaire.
The characteristics of the study population are shown in
Table 1. Overall more women than men participated.
Subjects with COPD according to the GOLD criteria (Gþ)
were older than subjects with no COPD according to the
GOLD criteria (G), regardless of concomitant self-
reported chronic bronchitis or emphysema or COPD (Qþ)
or not (Q) (p < 0.01).
Q/Gþ subjects had smoked more in terms of pack-
years compared with Qþ/G (p < 0.01). The proportion of
ex-smokers was significantly higher in both of the groups of
Table 1 General characteristics of the study population. Numbers and percentages are shown for categorical variables and
means with standard deviations are shown for continuous variables. (Qþ/Z self-reported chronic bronchitis or emphysema or
COPD or not, Gþ/ Z COPD according to GOLD or not).
Subjects Q/G
(n Z 252)
Q/Gþ
(n Z 90)
Qþ/G
(n Z 43)
Qþ/Gþ
(n Z 34)
Total
(n Z 419)
Male gender 99 (39.3%) 49 (54.4%) 12 (27.9%) 13 (38.2%) 173 (41.3%)
Female gender 153 (60.7%) 41 (45.6%) 31 (72.1%) 21 (61.8%) 246 (58.7%)
Age, years 60.1 (7.5) 64.1 (6.9) 60.0 (7.5) 65.5 (6.2) 61.4 (7.6)
Height, cm 169.4 (8.8) 171.3 (8.6) 167.7 (8.4) 168.3 (8.6) 169.5 (8.8)
BMI, kg/m2 26.2 (5.0) 26.0 (4.3) 29.3 (6.4) 27.2 (5.6) 26.6 (5.1)
Never-smokers 65 (25.8%) 3 (3.3%) 10 (23.3%) 1 (2.9%) 79 (18.9%)
Ex-smokers 58 (23.0%) 30 (33.3%) 25 (58.1%) 20 (58.8%) 133 (31.7%)
Current smokers 129 (51.2%) 57 (63.3%) 8 (18.6%) 13 (38.2%) 207 (49.4%)
Pack-years 19 (17) 32 (23) 19 (18) 30 (15) 23 (19)
COPD stage I 0 64 (71.1%) 0 18 (52.9%) 82 (19.6%)
COPD stage II 0 26 (28.9%) 0 10 (29.4%) 36 (8.6%)
COPD stage IIIeIV 0 0 0 6 (17.6%) 6 (1.4%)
Impulse oscillometry in detecting early manifestations of COPD 1119Qþ subjects compared to any of the groups of subjects with
Q (p < 0.05).
A diagnosis of COPD according to the GOLD criteria was
confirmed in 30% of the study population most subjects at
GOLD stage I.0
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Figure 2 The crude mean values of resistance and reactance
at different frequencies in the different study groups. (Qþ/
Q Z questionnaire positive or negative, Gþ/G Z fulfilling
the spirometric criteria for COPD according to GOLD or not).Spirometry and IOS results and report of
respiratory symptoms in the study population
The crude mean levels of resistance and reactance over the
full frequency range are plotted in Fig. 2 for the four
different study groups. Especially for the measurement of
resistance, both of the curves representing subjects
reporting respiratory symptoms (Qþ) are clearly separated
from both of the curves representing symptom-free
subjects (Q). We wanted further to analyse these differ-
ences, comparing subjects with and without respiratory
symptoms and with and without COPD according to GOLD.
Symptomatic subjects (Qþ) had statistically significantly
lower spirometry values (FEV1, VC, FEV1/VC) than non-
symptomatic subjects (Q) (Table 2a). Qþ subjects also
had statistically significantly higher pulmonary resistance
and lower (i.e. abnormal) reactance than Q subjects.
Subjects fulfilling the spirometric criteria for COPD
according to GOLD (Gþ) had significantly higher pulmonary
resistance and lower pulmonary reactance than subjects
not fulfilling the GOLD criteria (G), except for unadjusted
R20 (Table 2b). A higher proportion of Gþ subjects reported
use of any pulmonary medication, but no difference was
seen between the groups regarding report of long-standing
cough and symptoms characteristic of chronic bronchitis. As
expected, Gþ subjects had significantly lower FEV1 and
lower FEV1/VC than G subjects.
In Table 3 all 4 study groups are compared. This shows
that among all Gþ subjects, lung function variables
according to spirometry were lower and pulmonary resis-
tance was higher and pulmonary reactance was lower for
Qþ subjects compared to Q subjects (except for VC% PN,
p Z 0.25 and R20, p Z 0.11) The same pattern was seen
among G subjects (except for FEV1/VC% PN, p Z 0.84).Gþ subjects had lower FEV1 and FEV1/VC than G
subjects, irrespective of symptoms.
While pulmonary resistance did not differ significantly
between Qþ/Gþ subjects and Qþ/G subjects, pulmonary
reactance was significantly lower among Qþ/Gþ subjects
than Qþ/G subjects (p < 0.05). The measurements with
forced oscillation thus identified differences between
Table 2a Comparison of spirometry and IOS results between Qþ and Q subjects (subjects with or without self-reported
chronic bronchitis or emphysema or COPD). Means with standard deviations are shown for continuous variables and numbers
and percentages are shown for categorical variables. Continuous variables not normally distributed (all unadjusted IOS values)
are presented as medians and 80% central ranges. Geometric means are adjusted for gender and age. PN Z predicted normal
value. (Qþ/ Z self-reported chronic bronchitis or emphysema or COPD or not).
Qþ
(n Z 77)
Q
(n Z 342)
p-value
FEV1% PN 90 (23) 101 (15) <0.001
VC% PN 106 (19) 111 (14) 0.015
FEV1/VC 0.70 0.74 0.003
FEV1/VC% PN 90 (17) 97 (10) <0.001
R5 (kPa/(L/s)) 0.37 (0.23e0.57) 0.30 (0.19e0.47) <0.001
R5 geometric mean 0.36 0.30 <0.001
R20 (kPa/(L/s)) 0.26 (0.19e0.38) 0.23 (0.16e0.35) 0.004
R20 geometric mean 0.26 0.23 0.004
R5eR20 (kPa/(L/s)) 0.11 (0.04e0.23) 0.06 (0.02e0.14) <0.001
R5eR20 geometric mean 0.09 0.06 <0.001
X5 (kPa/(L/s)) 0.12 (0.31 to 0.05) 0.08 (0.16 to 0.04) <0.001
X5 geometric mean 0.11 0.08 <0.001
AX 0.49 (0.08e1.88) 0.20 (0.06e0.83) <0.001
AX geometric mean 0.40 0.22 <0.001
Symptoms of CB 24 (31.2%) 30 (8.8%) <0.001
Long-standing cough 30 (39.0%) 49 (14.3%) <0.001
Any use of pulmonary medication 29 (37.7%) 12 (3.5%) <0.001
1120 S. Frantz et al.symptomatic and asymptomatic subjects not revealed by
spirometry. For pulmonary resistance and reactance, higher
values for unadjusted R5 and R20 were observed for Qþ/G
subjects than for Q/Gþ subjects (p < 0.05). After adjust-
ments for gender and age, no differences were observed.Table 2b Comparison of spirometry and IOS results between Gþ
the GOLD criteria). Means with standard deviations are shown for
for categorical variables. Continuous variables not normally distr
and 80% central ranges. Geometric means are adjusted for gend
according to GOLD or not).
Gþ
(n Z 124)
FEV1% PN 85 (18)
VC% PN 110 (18)
FEV1/VC 0.62
FEV1/VC% PN 81 (11)
R5 (kPa/(L/s)) 0.32 (0.20e0.57)
R5 geometric mean 0.34
R20 (kPa/(L/s)) 0.23 (0.16e0.36)
R20 geometric mean 0.25
R5eR20 (kPa/(L/s)) 0.08 (0.03e0.21)
R5eR20 geometric mean 0.07
X5 (kPa/(L/s)) 0.10 (0.25 to 
X5 geometric mean 0.10
AX 0.34 (0.09e1.54)
AX geometric mean 0.33
Symptoms of CB 21 (16.9%)
Long-standing cough 26 (21.0%)
Any use of pulmonary medication 21 (16.9%)Discussion
Results from this study suggest that subjects with self-
reported chronic bronchitis or emphysema or COPD (Qþ)
have a higher pulmonary resistance and lower pulmonaryand G subjects (subjects with or without COPD according to
continuous variables and numbers and percentages are shown
ibuted (all unadjusted IOS values) are presented as medians
er and age. PN Z predicted normal value. (Gþ/ Z COPD
G
(n Z 295)
p-value
104 (14) <0.001
110 (14) 0.629
0.78 <0.001
102 (6) <0.001
0.30 (0.19e0.49) 0.029
0.30 0.002
0.24 (0.16e0.35) 0.505
0.23 0.049
0.06 (0.02e0.15) 0.013
0.06 0.023
0.05) 0.08 (0.16 to 0.04) <0.001
0.08 <0.001
0.20 (0.06e0.86) <0.001
0.21 <0.001
33 (11.1%) 0.098
53 (18.0%) 0.433
20 (6.8%) <0.001
Table 3 Spirometry, IOS and questionnaire results at the study visit. Means with standard deviations are shown for continuous
variables and numbers and percentages are shown for categorical variables. For IOS variables geometric means (adjusted for
gender and age) are shown. PNZ predicted normal value. Letters a, b, c and d show pair wise significant comparisons between
indicated groups (p < 0.05). (Qþ/Z self-reported chronic bronchitis or emphysema or COPD or not, Gþ/Z COPD according
to GOLD or not).
Q/G (a)
(n Z 252)
Q/Gþ (b)
(n Z 90)
Qþ/G (c)
(n Z 43)
Qþ/Gþ (d)
(n Z 34)
FEV1% PN 105
b,c,d (13) 87a,c,d (13) 100a,b,d (15) 78a,b,c (25)
VC% PN 110c (14) 111c (16) 105a,b (16) 108 (22)
FEV1/VC 0.78
b,d 0.64a,c,d 0.79b,d 0.58a,b,c
FEV1/VC% PN 102
b,d (6) 83a,c,d (7) 102b,d (7) 76a,b,c (16)
R5 (kPa/(L/s)) 0.29b,c,d 0.32a,d 0.35a 0.39a,b
R20 (kPa/(L/s)) 0.23c,d 0.24 0.25 0.27a
R5eR20 (kPa/(L/s)) 0.06c,d 0.07d 0.08a 0.10a,b
X5 (kPa/(L/s)) 0.08b,c,d 0.09a,d 0.10a,d 0.13a,b,c
AX 0.19b,c,d 0.27a,d 0.31a,d 0.55a,b,c
Symptoms of CB 18c,d (7.1%) 12c (13.3%) 15a,b (34.9%) 9a (26.5%)
Long-standing cough 36c,d (14.3%) 13c,d (14.4%) 17a,b (39.5%) 13a,b (38.2%)
Any use of pulmonary medication 5b,c,d (2.0%) 7a,c,d (7.8%) 15a,b (34.9%) 14a,b (41.2%)
Impulse oscillometry in detecting early manifestations of COPD 1121reactance than subjects without self-reported chronic
bronchitis or emphysema or COPD (Q), both in subjects
with and without spirometry diagnosed COPD according to
the GOLD criteria (Gþ and G). In addition, characteristics
of Qþ subjects were associated with more frequent reports
of symptoms characteristic of chronic bronchitis, long-
standing cough and use of pulmonary medication
compared with Gþ subjects. Together these findings
suggest that IOS could be of interest for getting increased
understanding of relationships between underlying disease
mechanisms of COPD, for example small airway disease and
clinically important symptoms. IOS may be complementary
to spirometry for this purpose. Furthermore, it seems
conceivable that IOS would be of value for detection of
individuals that already have developed typical patholog-
ical airway changes (i.e. small airway disease) for COPD,
even though not yet meeting the GOLD diagnosis criteria.
Worldwide, COPD is underdiagnosed as well as detected
too late in its course, due to factors such as underuse of
spirometry and patient delay.1,21,22 Early detection is of
importance to get the best possibility to intervene phar-
macologically and with other treatments. IOS seems to have
the potential to evaluate further the occurrence of distal
airway pathology, an important component of COPD,12e14,23
by measuring resistance and reactance. Since IOS is a non-
invasive method that requires minimal active engagement
by the patient it could perhaps also be used routinely with
the purpose of facilitate early detection of COPD. Since
forced oscillations measurements are made during quiet
breathing at functional residual capacity (FRC), forced
breathing manoeuvres which may affect bronchial tone are
avoided. In theory, elastic properties of the lung are
reflected in the low frequencies of reactance (distal
airways) and inertial properties are reflected in the high
frequencies of reactance (central airways).24 For resis-
tance, the theory is that resistance at low frequencies
represents total airway resistance, and resistance at high
frequencies represents central airway resistance, proposing
that the difference between these two is a surrogate forperipheral airway resistance.9 Already in the 1980s Cle´ment
et al.25 could separate healthy subjects from subjects with
respiratory complaints, associated or not with a reduced
FEV1. This group also studied differences between smokers
and non-smokers with normal spirometry without finding
any significant differences in forced oscillation.26 A
previous study of respiratory impedance in a large sample
of subjects referred for routine spirometry has shown that
the impedance measurements contributed significantly to
the discrimination between subjects with and without
marked respiratory complaints.27 A recent study has also
shown that IOS measurements can be used to define
different subgroups of COPD patients.28
Symptoms of long-standing cough and symptoms char-
acteristic of chronic bronchitis were more frequent among
Qþ subjects than Gþ subjects. There was no significant
difference concerning the report of long-standing cough
and symptoms characteristic of chronic bronchitis
comparing Gþ and G subjects.
It has been shown that subjects with respiratory symp-
toms have a high risk of developing COPD2,3,29 although
there are conflicting results.4 Symptoms also have
a predictive value among COPD patients, for example it has
been shown that dyspnoea better predict 5-year survival
than FEV1 in this group.
30 Cough and sputum production
may be symptoms of particular importance, since they may
be independent risk factors for FEV1 decline,
31 COPD hos-
pitalisation and also overall mortality.32,33
The fact that there is a poor relationship between
respiratory symptoms and spirometric variables1,5 may be
a further reason to use additional methods such as for
example IOS for characterisation of lung physiology,
particularly if these methods are validated, certified, non-
invasive and user friendly. Concerning IOS, there is a need
for more extensive studies of reference values.
A strength of this study is that the original study group is
population-based. In a representative population-based
sample, the prevalence of COPD is very low, and we
therefore performed a stratified sampling to increase the
1122 S. Frantz et al.proportion of subjects with COPD. Interpretation of the
information obtained by questionnaires always involves
uncertainties, which is a limitation that this study shares
with many other studies. Screening subjects for symptoms
is difficult; therefore there is a need for sensitive and
simple objective screening methods for future studies in
this field.
The GOLD criteria for a COPD diagnosis are based on
a fixed cut-off FEV1/VC ratio of 0.7. This leads to a risk of
overestimation of COPD especially in elderly men.34 Still,
we preferred to apply the fixed value since also subjects
with an FEV1/VC below 0.7 but above the lower limit of
normal for the age-adjusted predictions appear to risk an
unfavourable outcome.34
In conclusion, this study shows that subjects reporting
respiratory symptoms differ in lung mechanics measured by
the forced oscillation technique, whether they fulfil the
GOLD criteria of COPD or not. This may indicate that IOS
better captures changes in respiratory mechanics than
spirometry. As forced oscillation measurements are
considered better to reflect distal airway function than
spirometry, IOS may be useful for early detection of COPD.
Further research is, however, needed to establish this.
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